Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNASDAQ:CMPSNASDAQ:NRIXNASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.63+3.7%$7.40$5.90▼$34.11$556.92M2.191.45 million shs1.69 million shsCMPSCOMPASS Pathways$3.16+12.9%$4.04$2.25▼$8.54$295.65M2.251.20 million shs5.77 million shsNRIXNurix Therapeutics$11.71+2.8%$11.05$8.18▼$29.56$892.77M2.16837,006 shs618,590 shsPRAXPraxis Precision Medicines$43.17+2.7%$39.90$26.70▼$91.83$879.37M2.61366,461 shs202,892 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-2.39%-0.54%+1.80%+4.69%-72.35%CMPSCOMPASS Pathways+1.08%+19.15%-32.37%+0.36%-53.64%NRIXNurix Therapeutics-2.15%-4.92%+7.25%+8.79%-45.42%PRAXPraxis Precision Medicines-2.21%+1.01%+8.99%+17.23%+1.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.6291 of 5 stars4.32.00.00.02.32.51.3CMPSCOMPASS Pathways1.9351 of 5 stars3.42.00.00.01.70.80.6NRIXNurix Therapeutics1.1987 of 5 stars3.40.00.00.02.00.80.0PRAXPraxis Precision Medicines3.2383 of 5 stars4.42.00.00.03.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29165.92% UpsideCMPSCOMPASS Pathways 2.86Moderate Buy$17.00437.97% UpsideNRIXNurix Therapeutics 2.83Moderate Buy$30.18157.70% UpsidePRAXPraxis Precision Medicines 2.78Moderate Buy$92.11113.37% UpsideCurrent Analyst Ratings BreakdownLatest NRIX, PRAX, ARVN, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/23/2025CMPSCOMPASS PathwaysEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ In-Line$11.00 ➝ $6.006/12/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform$97.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/27/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$12.005/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/13/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$426.90M1.30N/AN/A$8.17 per share0.93CMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/ANRIXNurix Therapeutics$54.55M16.37N/AN/A$7.44 per share1.57PRAXPraxis Precision Medicines$8.55M102.85N/AN/A$23.90 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)CMPSCOMPASS Pathways-$155.12M-$1.99N/AN/AN/AN/A-81.75%-59.42%7/30/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.80N/AN/AN/A-369.40%-47.49%-36.10%7/10/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$10.72N/AN/AN/A-2,137.48%-50.42%-46.74%8/12/2025 (Estimated)Latest NRIX, PRAX, ARVN, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025ARVNArvinas-$0.87N/AN/AN/A$34.42 millionN/A7/10/2025Q2 2025NRIXNurix Therapeutics-$0.73N/AN/AN/A$16.26 millionN/A5/8/2025Q1 2025CMPSCOMPASS Pathways-$0.47-$0.44+$0.03-$0.24N/AN/A5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A4/8/2025Q1 2025NRIXNurix Therapeutics-$0.72-$0.67+$0.05-$0.67$12.78 million$18.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.584.58CMPSCOMPASS Pathways0.1110.1810.18NRIXNurix TherapeuticsN/A6.266.26PRAXPraxis Precision MedicinesN/A8.448.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%CMPSCOMPASS Pathways46.19%NRIXNurix TherapeuticsN/APRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%CMPSCOMPASS Pathways3.93%NRIXNurix Therapeutics7.40%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million69.54 millionOptionableCMPSCOMPASS Pathways12093.56 million89.89 millionOptionableNRIXNurix Therapeutics30076.24 million70.60 millionOptionablePRAXPraxis Precision Medicines11020.37 million19.82 millionOptionableNRIX, PRAX, ARVN, and CMPS HeadlinesRecent News About These CompaniesPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by BrokeragesJune 28 at 2:35 AM | marketbeat.comAssenagon Asset Management S.A. Sells 51,682 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)June 14, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)June 12, 2025 | marketbeat.comBank of America Corp DE Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)June 12, 2025 | marketbeat.comFormer head trader of Denver-based investing company pleads guilty to insider tradingJune 9, 2025 | finance.yahoo.comWeston man pleads guilty to insider trading offense that made him $220KJune 8, 2025 | stamfordadvocate.comSPraxis Precision Medicines (NASDAQ:PRAX) Trading Up 7.6% - Here's WhyJune 5, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | globenewswire.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Wellington Management Group LLPJune 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Holdings Reduced by Squarepoint Ops LLCJune 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 3, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Coverage Initiated by Analysts at OppenheimerJune 2, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial MarketsJune 1, 2025 | marketbeat.comPraxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock UpsideMay 7, 2025 | benzinga.comChardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy RecommendationMay 7, 2025 | msn.comPraxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor EventMay 5, 2025 | finance.yahoo.comPraxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)May 4, 2025 | finance.yahoo.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 2, 2025 | globenewswire.comPraxis Precision Medicine Stock Price, Quotes and Forecasts | NASDAQ:PRAX | BenzingaApril 21, 2025 | benzinga.comPraxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic EncephalopathiesApril 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRIX, PRAX, ARVN, and CMPS Company DescriptionsArvinas NASDAQ:ARVN$7.63 +0.27 (+3.67%) Closing price 04:00 PM EasternExtended Trading$7.70 +0.07 (+0.93%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.COMPASS Pathways NASDAQ:CMPS$3.16 +0.36 (+12.86%) Closing price 04:00 PM EasternExtended Trading$3.15 -0.01 (-0.32%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Nurix Therapeutics NASDAQ:NRIX$11.71 +0.32 (+2.81%) Closing price 04:00 PM EasternExtended Trading$11.85 +0.14 (+1.20%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Praxis Precision Medicines NASDAQ:PRAX$43.17 +1.12 (+2.66%) Closing price 04:00 PM EasternExtended Trading$42.57 -0.60 (-1.40%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
